Elevar Therapeutics, Inc. announced that the US FDA has granted rivoceranib with orphan drug designation for the treatment of HCC, the most common primary liver malignancy and is a leading cause of cancer-related death worldwide.
[Hepatic Cell News]
7992332
{7992332:EEEEEEEE}
apa
50
1
169164
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/